WO2003029184A1 - Derive d'ether de diaryle, son sel d'addition et son immunosuppresseur - Google Patents

Derive d'ether de diaryle, son sel d'addition et son immunosuppresseur Download PDF

Info

Publication number
WO2003029184A1
WO2003029184A1 PCT/JP2002/009864 JP0209864W WO03029184A1 WO 2003029184 A1 WO2003029184 A1 WO 2003029184A1 JP 0209864 W JP0209864 W JP 0209864W WO 03029184 A1 WO03029184 A1 WO 03029184A1
Authority
WO
WIPO (PCT)
Prior art keywords
ether derivative
diaryl ether
immunosuppressant
addition salt
diaryl
Prior art date
Application number
PCT/JP2002/009864
Other languages
English (en)
French (fr)
Inventor
Yasushi Kohno
Naoki Ando
Takahiro Tanase
Kazuhiko Kuriyama
Satoru Iwanami
Shinji Kudou
Original Assignee
Kyorin Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyorin Pharmaceutical Co., Ltd. filed Critical Kyorin Pharmaceutical Co., Ltd.
Priority to AT02768056T priority Critical patent/ATE463478T1/de
Priority to JP2003532439A priority patent/JP4152884B2/ja
Priority to US10/490,345 priority patent/US6963012B2/en
Priority to DE60235900T priority patent/DE60235900D1/de
Priority to EP02768056A priority patent/EP1431275B1/en
Priority to CA2460640A priority patent/CA2460640C/en
Publication of WO2003029184A1 publication Critical patent/WO2003029184A1/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/64—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cephalosporin Compounds (AREA)
  • Fats And Perfumes (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
PCT/JP2002/009864 2001-09-27 2002-09-25 Derive d'ether de diaryle, son sel d'addition et son immunosuppresseur WO2003029184A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AT02768056T ATE463478T1 (de) 2001-09-27 2002-09-25 Diaryletherderivat, dessen additionssalz und immunosuppressivum
JP2003532439A JP4152884B2 (ja) 2001-09-27 2002-09-25 ジアリールエーテル誘導体とその付加塩及び免疫抑制剤
US10/490,345 US6963012B2 (en) 2001-09-27 2002-09-25 Diaryl ether derivative, addition salt thereof, and immunosuppressant
DE60235900T DE60235900D1 (de) 2001-09-27 2002-09-25 Osuppressivum
EP02768056A EP1431275B1 (en) 2001-09-27 2002-09-25 Diaryl ether derivative, addition salt thereof, and immunosuppressant
CA2460640A CA2460640C (en) 2001-09-27 2002-09-25 Diaryl ether derivatives, salts thereof and immunosuppressive agents using the same

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2001-297400 2001-09-27
JP2001297400 2001-09-27
JP2002-216191 2002-07-25
JP2002216191 2002-07-25

Publications (1)

Publication Number Publication Date
WO2003029184A1 true WO2003029184A1 (fr) 2003-04-10

Family

ID=26623110

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/009864 WO2003029184A1 (fr) 2001-09-27 2002-09-25 Derive d'ether de diaryle, son sel d'addition et son immunosuppresseur

Country Status (7)

Country Link
US (1) US6963012B2 (ja)
EP (1) EP1431275B1 (ja)
JP (1) JP4152884B2 (ja)
AT (1) ATE463478T1 (ja)
CA (1) CA2460640C (ja)
DE (1) DE60235900D1 (ja)
WO (1) WO2003029184A1 (ja)

Cited By (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005063671A1 (ja) * 2003-12-25 2005-07-14 Sankyo Company, Limited エーテル誘導体
WO2006009092A1 (ja) * 2004-07-16 2006-01-26 Kyorin Pharmaceutical Co., Ltd. 効果的な医薬の使用法及び副作用発現の防御に関する方法
WO2006010630A1 (en) 2004-07-30 2006-02-02 Novartis Ag Compound formulations of 2-amino-1, 3-propanediol compounds
WO2006058316A1 (en) 2004-11-29 2006-06-01 Novartis Ag Dosage regimen of an s1p receptor agonist
JP2006524660A (ja) * 2003-04-30 2006-11-02 ノバルティス アクチエンゲゼルシャフト スフィンゴシン−１−ホスフェートレセプターモジュレーターとしての、アミノプロパノール誘導体
JP2007509046A (ja) * 2003-10-15 2007-04-12 ノバルティス アクチエンゲゼルシャフト アミノアルカノール誘導体
WO2007043433A1 (ja) 2005-10-07 2007-04-19 Kyorin Pharmaceutical Co., Ltd. ２－アミノ－１，３－プロパンジオール誘導体を有効成分とする肝臓疾患治療剤および肝臓疾患治療方法
EP1797892A1 (en) 2003-09-03 2007-06-20 Novartis AG Use of modified cyclosporins for the treatment of HCV disorders
WO2007091501A1 (ja) 2006-02-06 2007-08-16 Kyorin Pharmaceutical Co., Ltd. ２－アミノ－１，３－プロパンジオール誘導体を有効成分とする炎症性腸疾患治療剤又は炎症性腸疾患の治療方法
WO2007126042A1 (ja) 2006-04-28 2007-11-08 Mitsubishi Tanabe Pharma Corporation ２－アミノブタノール化合物及びその医薬用途
JP2007536310A (ja) * 2004-05-03 2007-12-13 ノバルティス アクチエンゲゼルシャフト Ｓ１ｐ受容体アゴニストおよびｊａｋ３キナーゼ阻害剤を含む、組合せ剤
WO2008016133A1 (fr) 2006-08-04 2008-02-07 Daiichi Sankyo Company, Limited Enzyme de phosphorylation d'un médicament
WO2008018447A1 (fr) 2006-08-08 2008-02-14 Kyorin Pharmaceutical Co., Ltd. Dérivé d'aminoalcool et immunodépresseur le contenant en tant que principe actif
WO2008018427A1 (fr) 2006-08-08 2008-02-14 Kyorin Pharmaceutical Co., Ltd. Dérivé d'ester de l'acide aminophosphorique et modulateur du récepteur s1p contenant ledit dérivé en tant que principe actif
EP1944026A2 (en) 2002-05-16 2008-07-16 Novartis AG Use of EDG receptor binding agents in cancer
EP2008650A2 (en) 2003-04-08 2008-12-31 Novartis AG Solid oral composition comprising a S 1 P receptor agonist and a sugar alcohol
US7482491B2 (en) 2002-09-19 2009-01-27 Kyorin Pharmaceutical Co., Ltd. Amino alcohol derivative, addition salt thereof, and immunosuppressant
JP2009507810A (ja) * 2005-09-09 2009-02-26 ノバルティス アクチエンゲゼルシャフト 自己免疫性疾患の処置
JP2009040794A (ja) * 2001-09-27 2009-02-26 Kyorin Pharmaceut Co Ltd ジアリールスルフィド誘導体とその付加塩及び免疫抑制剤
WO2009142195A1 (ja) 2008-05-20 2009-11-26 杏林製薬株式会社 寛解導入維持剤
EP2216019A2 (en) 2005-03-04 2010-08-11 Novartis AG Ophthalmic uses of S1P receptor modulators
WO2010089210A1 (en) 2009-02-04 2010-08-12 Syngenta Limited Novel herbicides
WO2010089211A1 (en) 2009-02-04 2010-08-12 Syngenta Limited Novel herbicides
WO2010115981A1 (en) 2009-04-10 2010-10-14 Novartis Ag 7-azadispiro [3.0.4.1] decane-8-carboxamides as hepatitis c virus inhibitors
WO2010116248A1 (en) 2009-04-10 2010-10-14 Novartis Ag Organic compounds and their uses
EP2251007A2 (en) 2002-09-24 2010-11-17 Novartis AG Sphingosine-1-phosphate (S1P) receptor agonists for use in the treatment of demyelinating diseases
WO2011004604A1 (ja) 2009-07-09 2011-01-13 杏林製薬株式会社 ジフェニルスルフィド誘導体及びそれらを有効成分とする医薬
JP2011502124A (ja) * 2007-10-31 2011-01-20 モメンティブ パフォーマンス マテリアルズ インコーポレイテッド ハロ官能性シラン、その調製プロセス、それを含むゴム組成物およびそれらから製造される製品
CN101242829B (zh) * 2005-06-24 2011-05-18 第一三共株式会社 含有ppar调节剂的药物组合物
EP2351560A1 (en) 2005-01-04 2011-08-03 Novartis AG Treatment Of HCV infections with FTY720
WO2011138393A1 (en) 2010-05-06 2011-11-10 Novartis Ag Treatment of autoimmune diseases
WO2011138398A1 (en) 2010-05-06 2011-11-10 Novartis Ag Dosage regimen of diaryl sulfide derivatives
WO2012048235A1 (en) 2010-10-08 2012-04-12 Novartis Ag Vitamin e formulations of sulfamide ns3 inhibitors
EP2465492A1 (en) 2007-10-12 2012-06-20 Novartis AG Compositions comprising sphingosine I phosphate (sip) receptor modulators
WO2012086184A1 (ja) 2010-12-21 2012-06-28 杏林製薬株式会社 ジフェニルスルフィド誘導体及びそれらを有効成分とする医薬
EP2518079A2 (en) 2006-04-11 2012-10-31 Novartis AG HCV/HIV inhibitors and their uses
US8519006B2 (en) 2003-12-19 2013-08-27 Novartis Ag Use of sphingosine-1 phosphate (S1P) receptor agonists for the treatment of brain degenerative diseases
WO2013161816A1 (ja) 2012-04-23 2013-10-31 田辺三菱製薬株式会社 アミン化合物及びその医薬用途
JP2014520832A (ja) * 2011-07-13 2014-08-25 ビーエーエスエフ ソシエタス・ヨーロピア 殺菌性置換２−［２−ハロゲンアルキル−４−（フェノキシ）−フェニル］−１−［１，２，４］トリアゾール−１−イル−エタノール化合物
JP2014523887A (ja) * 2011-07-06 2014-09-18 中国医学科学院薬物研究所 アミノプロパンジオール誘導体、準備、および医薬品組成物および用途
WO2020022507A1 (ja) 2018-07-27 2020-01-30 杏林製薬株式会社 造血幹細胞移植を受けた患者における血液悪性腫瘍の再発抑制剤

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003202495B2 (en) 2002-01-11 2006-07-20 Sankyo Company, Limited Amino alcohol derivative or phosphonic acid derivative and medicinal composition containing these
NZ549162A (en) * 2004-02-24 2009-12-24 Sankyo Co Amino-pyrrol alcohol compounds
TW200611687A (en) * 2004-07-29 2006-04-16 Sankyo Co Pharmaceutical compositions used for immunosuppressant
ES2563034T3 (es) 2004-10-12 2016-03-10 Kyorin Pharmaceutical Co., Ltd. Procedimiento para producir hidrocloruro de 2-amino-2-[2-[4-(3-benciloxifeniltio)-2-clorofenil]etil]-1,3-propanodiol e hidratos del mismo, e intermedios para la producción de los mismos
AR057455A1 (es) * 2005-07-22 2007-12-05 Merck & Co Inc Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
JP5341754B2 (ja) 2007-06-14 2013-11-13 田辺三菱製薬株式会社 アミン化合物及びその医薬用途
US8476305B2 (en) 2008-02-07 2013-07-02 Kyorin Pharmaceutical Co., Ltd. Therapeutic agent or prophylactic agent for inflammatory bowel disease comprising amino alcohol derivative as active ingredient
AU2009227629B2 (en) 2008-03-17 2014-09-04 Actelion Pharmaceuticals Ltd Dosing regimen for a selective S1P1 receptor agonist
EP2292594A4 (en) * 2008-05-19 2014-10-15 Kyorin Seiyaku Kk PROCESS FOR PRODUCING OPTICALLY ACTIVE AMINOALCOOL DERIVATIVE
KR101148098B1 (ko) 2010-04-30 2012-05-22 한국화학연구원 1-［4-（4-니트로-페녹시）-페닐］-프로판-1-온을 유효성분으로 함유하는 톡소포자충 및 콕시디움에 기인한 질환의 예방 및 치료용 조성물
US9137996B2 (en) 2011-07-15 2015-09-22 Basf Se Fungicidal alkyl- and aryl-substituted 2[-2-chloro-4-(dihalo-phenoxy)-phenyl]-1-[1,2,4]triazol-1-yl-ethanol compounds
KR20140057550A (ko) 2011-07-15 2014-05-13 바스프 에스이 살진균성의 알킬-치환된 2-[2-클로로-4-(4-클로로-페녹시)-페닐]-1-[1,2,4]트리아졸-1-일-에탄올 화합물
CN103717577B (zh) 2011-08-15 2016-06-15 巴斯夫欧洲公司 杀真菌的取代的1-{2-环基氧基-2-[2-卤代-4-(4-卤代苯氧基)苯基]乙基}-1h-[1,2,4]三唑化合物
EA201400231A1 (ru) 2011-08-15 2014-07-30 Басф Се Фунгицидные замещенные 1-{2-[2-галоген-4-(4-галогенфенокси)фенил]-2-алкокси-2-алкинил/алкенилэтил}-1н-[1,2,4]триазольные соединения
CN103748082B (zh) 2011-08-15 2016-03-02 巴斯夫欧洲公司 杀真菌的取代的1-{2-[2-卤代-4-(4-卤代苯氧基)苯基]-2-烷氧基-3-甲基丁基}-1h-[1,2,4]三唑化合物
PL2934147T3 (pl) 2012-12-20 2020-06-29 BASF Agro B.V. Kompozycje zawierające związki triazolowe
EA033780B1 (ru) 2013-01-09 2019-11-25 Basf Agro Bv Способ получения замещенных оксиранов и триазолов
RU2669997C2 (ru) 2013-07-08 2018-10-17 Басф Агро Б.В. Композиции, содержащие триазольное соединение и биопестицид
CN104844486B (zh) * 2014-02-17 2018-10-30 中国医学科学院药物研究所 胺基丙二醇类衍生物、其制备方法和其药物组合物与用途
AU2015281187B2 (en) 2014-06-25 2018-10-04 BASF Agro B.V. Pesticidal compositions
EP3214937B1 (en) 2014-11-07 2024-07-03 Basf Se Pesticidal mixtures
WO2017157920A1 (en) 2016-03-16 2017-09-21 Basf Se Use of tetrazolinones for combating resistant phytopathogenic fungi on fruits
BR112018068705B1 (pt) 2016-03-16 2022-09-06 Basf Se Método para controlar fungos fitopatogênicos
EP3429357A1 (en) 2016-03-16 2019-01-23 Basf Se Use of tetrazolinones for combating resistant phytopathogenic fungi on cereals

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604229A (en) * 1992-10-21 1997-02-18 Yoshitomi Pharmaceutical Industries, Ltd. 2-amino-1,3-propanediol compound and immunosuppressant
EP1002792A1 (en) * 1997-04-04 2000-05-24 Yoshitomi Pharmaceutical Industries, Ltd. 2-aminopropane-1,3-diol compounds, medicinal use thereof, and intermediates in synthesizing the same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69524962T4 (de) * 1994-08-22 2003-08-28 Mitsubishi Pharma Corp., Osaka Benzolderivate und deren medizinische verwendung

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604229A (en) * 1992-10-21 1997-02-18 Yoshitomi Pharmaceutical Industries, Ltd. 2-amino-1,3-propanediol compound and immunosuppressant
EP1002792A1 (en) * 1997-04-04 2000-05-24 Yoshitomi Pharmaceutical Industries, Ltd. 2-aminopropane-1,3-diol compounds, medicinal use thereof, and intermediates in synthesizing the same

Cited By (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009040794A (ja) * 2001-09-27 2009-02-26 Kyorin Pharmaceut Co Ltd ジアリールスルフィド誘導体とその付加塩及び免疫抑制剤
EP1955696A2 (en) 2002-05-16 2008-08-13 Novartis AG Use of EDG receptor binding agents in cancer
EP1944026A2 (en) 2002-05-16 2008-07-16 Novartis AG Use of EDG receptor binding agents in cancer
US7763752B2 (en) 2002-09-19 2010-07-27 Kyorin Pharmaceutical Co., Ltd. Amino alcohol derivatives, salts thereof and immunosuppresive agents
US7482491B2 (en) 2002-09-19 2009-01-27 Kyorin Pharmaceutical Co., Ltd. Amino alcohol derivative, addition salt thereof, and immunosuppressant
EP2251007A2 (en) 2002-09-24 2010-11-17 Novartis AG Sphingosine-1-phosphate (S1P) receptor agonists for use in the treatment of demyelinating diseases
EP2255798A2 (en) 2002-09-24 2010-12-01 Novartis AG Sphingosine-1-phosphate receptor agonists for use in the treatment of optic neuritis
EP2008650A2 (en) 2003-04-08 2008-12-31 Novartis AG Solid oral composition comprising a S 1 P receptor agonist and a sugar alcohol
RU2475237C2 (ru) * 2003-04-08 2013-02-20 Новартис Аг Предназначенная для перорального применения фармацевтическая композиция
DE202004021680U1 (de) 2003-04-08 2010-04-22 Novartis Ag Feste pharmazeutische Zusammensetzung
RU2475236C2 (ru) * 2003-04-08 2013-02-20 Новартис Аг Способ получения фармацевтической композиции
EP2769713A1 (en) 2003-04-08 2014-08-27 Novartis AG Solid oral composition comprising a S1P receptor agonist and a sugar alcohol
EP2316431A1 (en) 2003-04-08 2011-05-04 Novartis AG Solid oral composition comprising a S1P receptor agonist and a sugar alcohol
JP2006524660A (ja) * 2003-04-30 2006-11-02 ノバルティス アクチエンゲゼルシャフト スフィンゴシン−１−ホスフェートレセプターモジュレーターとしての、アミノプロパノール誘導体
EP1797892A1 (en) 2003-09-03 2007-06-20 Novartis AG Use of modified cyclosporins for the treatment of HCV disorders
JP2007509046A (ja) * 2003-10-15 2007-04-12 ノバルティス アクチエンゲゼルシャフト アミノアルカノール誘導体
US8519006B2 (en) 2003-12-19 2013-08-27 Novartis Ag Use of sphingosine-1 phosphate (S1P) receptor agonists for the treatment of brain degenerative diseases
WO2005063671A1 (ja) * 2003-12-25 2005-07-14 Sankyo Company, Limited エーテル誘導体
JP2007536310A (ja) * 2004-05-03 2007-12-13 ノバルティス アクチエンゲゼルシャフト Ｓ１ｐ受容体アゴニストおよびｊａｋ３キナーゼ阻害剤を含む、組合せ剤
EP2363149A1 (en) 2004-05-03 2011-09-07 Novartis AG Combinations comprising a S1P receptor agonist and a JAK3 kinase inhibitor
AU2005264431B2 (en) * 2004-07-16 2010-08-19 Kyorin Pharmaceutical Co., Ltd. Method of effectively using medicine and method concerning prevention of side effect
JPWO2006009092A1 (ja) * 2004-07-16 2008-05-01 杏林製薬株式会社 効果的な医薬の使用法及び副作用発現の防御に関する方法
EP1772145A4 (en) * 2004-07-16 2009-07-08 Kyorin Seiyaku Kk METHOD FOR EFFECTIVELY APPLYING A MEDICAMENT AND METHOD FOR PREVENTING SIDE EFFECTS
WO2006009092A1 (ja) * 2004-07-16 2006-01-26 Kyorin Pharmaceutical Co., Ltd. 効果的な医薬の使用法及び副作用発現の防御に関する方法
US7807854B2 (en) 2004-07-16 2010-10-05 Kyorin Pharmaceutical Co., Ltd. Effective use method of medicaments and method of preventing expression of side effect
US7781617B2 (en) 2004-07-16 2010-08-24 Kyorin Pharmaceutical Co., Ltd Effective use method of medicaments and method of preventing expression of side effect
WO2006010630A1 (en) 2004-07-30 2006-02-02 Novartis Ag Compound formulations of 2-amino-1, 3-propanediol compounds
EP2829268A1 (en) 2004-07-30 2015-01-28 Novartis AG Compound formulations of 2-amino-1,3-propanediol compounds
WO2006058316A1 (en) 2004-11-29 2006-06-01 Novartis Ag Dosage regimen of an s1p receptor agonist
EP2384749A1 (en) 2004-11-29 2011-11-09 Novartis AG Dosage regimen of an S1P receptor agonist
EP2359821A1 (en) 2004-11-29 2011-08-24 Novartis AG Dosage regimen of an s1p receptor agonist
EP2351560A1 (en) 2005-01-04 2011-08-03 Novartis AG Treatment Of HCV infections with FTY720
EP2216019A2 (en) 2005-03-04 2010-08-11 Novartis AG Ophthalmic uses of S1P receptor modulators
CN101242829B (zh) * 2005-06-24 2011-05-18 第一三共株式会社 含有ppar调节剂的药物组合物
JP2015025002A (ja) * 2005-09-09 2015-02-05 ノバルティス アーゲー 自己免疫性疾患の処置剤
JP2009507810A (ja) * 2005-09-09 2009-02-26 ノバルティス アクチエンゲゼルシャフト 自己免疫性疾患の処置
JP2013010802A (ja) * 2005-09-09 2013-01-17 Novartis Ag 自己免疫性疾患の処置剤
EP2295049A1 (en) 2005-09-09 2011-03-16 Novartis AG Treatment of autoimmune diseases
WO2007043433A1 (ja) 2005-10-07 2007-04-19 Kyorin Pharmaceutical Co., Ltd. ２－アミノ－１，３－プロパンジオール誘導体を有効成分とする肝臓疾患治療剤および肝臓疾患治療方法
JP5116476B2 (ja) * 2005-10-07 2013-01-09 杏林製薬株式会社 ２−アミノ−１，３−プロパンジオール誘導体を有効成分とする肝臓疾患治療剤および肝臓疾患治療方法
US8048928B2 (en) 2005-10-07 2011-11-01 Kyorin Pharmaceutical Co., Ltd. Therapeutic agent for treating liver disease containing 2-amino-1,3-propanediol derivative as active ingredient, and method for treating liver disease
EP2520291A1 (en) 2006-02-06 2012-11-07 Kyorin Pharmaceutical Co., Ltd. Therapeutic agent for inflammatory bowel disease containing as active ingredient 2-amino-1,3-propanediol derivative, or method for treating inflammatory bowel disease
HRP20080421B1 (hr) * 2006-02-06 2015-07-17 Kyorin Pharmaceutical Co., Ltd. Terapijsko sredstvo za upalnu bolest crijeva koje kao aktivni sastojak sadrži derivat 2-amino-1,3-propandiola, ili postupak za lijeäśenje upalne bolesti crijeva
JP5042042B2 (ja) * 2006-02-06 2012-10-03 杏林製薬株式会社 ２−アミノ−１，３−プロパンジオール誘導体を有効成分とする炎症性腸疾患治療剤又は炎症性腸疾患の治療方法
WO2007091501A1 (ja) 2006-02-06 2007-08-16 Kyorin Pharmaceutical Co., Ltd. ２－アミノ－１，３－プロパンジオール誘導体を有効成分とする炎症性腸疾患治療剤又は炎症性腸疾患の治療方法
EP2518079A2 (en) 2006-04-11 2012-10-31 Novartis AG HCV/HIV inhibitors and their uses
WO2007126042A1 (ja) 2006-04-28 2007-11-08 Mitsubishi Tanabe Pharma Corporation ２－アミノブタノール化合物及びその医薬用途
WO2008016133A1 (fr) 2006-08-04 2008-02-07 Daiichi Sankyo Company, Limited Enzyme de phosphorylation d'un médicament
US8273748B2 (en) * 2006-08-08 2012-09-25 Kyorin Pharmaceutical Co., Ltd. Amino alcohol derivative and immunosuppresive agent having same as an active ingredient
WO2008018427A1 (fr) 2006-08-08 2008-02-14 Kyorin Pharmaceutical Co., Ltd. Dérivé d'ester de l'acide aminophosphorique et modulateur du récepteur s1p contenant ledit dérivé en tant que principe actif
WO2008018447A1 (fr) 2006-08-08 2008-02-14 Kyorin Pharmaceutical Co., Ltd. Dérivé d'aminoalcool et immunodépresseur le contenant en tant que principe actif
EP3120833A1 (en) 2007-10-12 2017-01-25 Novartis Ag Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators
EP2465492A1 (en) 2007-10-12 2012-06-20 Novartis AG Compositions comprising sphingosine I phosphate (sip) receptor modulators
EP3733162A1 (en) 2007-10-12 2020-11-04 Novartis AG Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators
EP3733161A1 (en) 2007-10-12 2020-11-04 Novartis AG Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators
EP2653154A1 (en) 2007-10-12 2013-10-23 Novartis AG Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators
JP2011502124A (ja) * 2007-10-31 2011-01-20 モメンティブ パフォーマンス マテリアルズ インコーポレイテッド ハロ官能性シラン、その調製プロセス、それを含むゴム組成物およびそれらから製造される製品
JPWO2009142195A1 (ja) * 2008-05-20 2011-09-29 杏林製薬株式会社 寛解導入維持剤
RU2505288C2 (ru) * 2008-05-20 2014-01-27 Киорин Фармасьютикал Ко., Лтд. Средства поддержания индуцированной ремиссии
WO2009142195A1 (ja) 2008-05-20 2009-11-26 杏林製薬株式会社 寛解導入維持剤
WO2010089210A1 (en) 2009-02-04 2010-08-12 Syngenta Limited Novel herbicides
WO2010089211A1 (en) 2009-02-04 2010-08-12 Syngenta Limited Novel herbicides
WO2010115981A1 (en) 2009-04-10 2010-10-14 Novartis Ag 7-azadispiro [3.0.4.1] decane-8-carboxamides as hepatitis c virus inhibitors
WO2010116248A1 (en) 2009-04-10 2010-10-14 Novartis Ag Organic compounds and their uses
WO2011004604A1 (ja) 2009-07-09 2011-01-13 杏林製薬株式会社 ジフェニルスルフィド誘導体及びそれらを有効成分とする医薬
WO2011138398A1 (en) 2010-05-06 2011-11-10 Novartis Ag Dosage regimen of diaryl sulfide derivatives
WO2011138393A1 (en) 2010-05-06 2011-11-10 Novartis Ag Treatment of autoimmune diseases
WO2012048235A1 (en) 2010-10-08 2012-04-12 Novartis Ag Vitamin e formulations of sulfamide ns3 inhibitors
WO2012086184A1 (ja) 2010-12-21 2012-06-28 杏林製薬株式会社 ジフェニルスルフィド誘導体及びそれらを有効成分とする医薬
JP2014523887A (ja) * 2011-07-06 2014-09-18 中国医学科学院薬物研究所 アミノプロパンジオール誘導体、準備、および医薬品組成物および用途
JP2014520832A (ja) * 2011-07-13 2014-08-25 ビーエーエスエフ ソシエタス・ヨーロピア 殺菌性置換２−［２−ハロゲンアルキル−４−（フェノキシ）−フェニル］−１−［１，２，４］トリアゾール−１−イル−エタノール化合物
WO2013161816A1 (ja) 2012-04-23 2013-10-31 田辺三菱製薬株式会社 アミン化合物及びその医薬用途
WO2020022507A1 (ja) 2018-07-27 2020-01-30 杏林製薬株式会社 造血幹細胞移植を受けた患者における血液悪性腫瘍の再発抑制剤

Also Published As

Publication number Publication date
CA2460640A1 (en) 2003-04-10
EP1431275A4 (en) 2006-05-31
DE60235900D1 (de) 2010-05-20
JPWO2003029184A1 (ja) 2005-01-13
EP1431275B1 (en) 2010-04-07
JP4152884B2 (ja) 2008-09-17
EP1431275A1 (en) 2004-06-23
ATE463478T1 (de) 2010-04-15
US6963012B2 (en) 2005-11-08
CA2460640C (en) 2011-03-29
US20040242654A1 (en) 2004-12-02

Similar Documents

Publication Publication Date Title
WO2003029184A1 (fr) Derive d'ether de diaryle, son sel d'addition et son immunosuppresseur
WO2003029205A1 (fr) Derive de sulfure de diaryle, son sel d'addition et immunosuppresseur
USD519296S1 (en) Sofa
HK1071510A1 (en) Acetylene derivatives having mglur 5 antagonistic activity
WO2003017760A3 (de) Fungizide wirkstoffkombinationen
USD459404S1 (en) Game ball
WO2004056785A3 (en) Uracils having a herbicidal activity
USD458935S1 (en) Communications card
WO2003028466A3 (en) Herbicidal composition
USD454438S1 (en) Gardening kneeling assistor
USD473127S1 (en) Spring clip
USD454049S1 (en) Combined door knob and rose
USD468387S1 (en) Playset
USD460973S1 (en) Lawn mower
USD462099S1 (en) Exerciser
USD488415S1 (en) Exhaust guard
USD444516S1 (en) Dumbbell
USD453371S1 (en) Spray gun
USD456675S1 (en) Lawn mower
USD453548S1 (en) Spray gun
USD465883S1 (en) Hair band
USD473157S1 (en) Planter
USD457251S1 (en) Landscape edging
USD476780S1 (en) Animal cabinet
USD449671S1 (en) Spray gun

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003532439

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002768056

Country of ref document: EP

Ref document number: 2460640

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 10490345

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2002768056

Country of ref document: EP